Frequency Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Frequency Therapeutics's estimated annual revenue is currently $24M per year.
- Frequency Therapeutics received $42.0M in venture funding in January 2019.
- Frequency Therapeutics's estimated revenue per employee is $240,200
- Frequency Therapeutics's total funding is $180.3M.
- Frequency Therapeutics's current valuation is $177.9M. (January 2022}
Employee Data
- Frequency Therapeutics has 100 Employees.
- Frequency Therapeutics grew their employee count by -9% last year.
Frequency Therapeutics Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -94% | N/A | N/A |
#2 | $2.6M | 17 | N/A | N/A | N/A |
#3 | $6M | 39 | -20% | $176.5M | N/A |
#4 | $4.5M | 29 | N/A | N/A | N/A |
#5 | $2.6M | 17 | N/A | N/A | N/A |
#6 | N/A | 145 | -21% | $39.5M | N/A |
#7 | N/A | 0 | N/A | $9.5M | N/A |
#8 | $15.9M | 159 | -39% | $135M | N/A |
#9 | $1.7M | 11 | 57% | $20.9M | N/A |
#10 | $2.8M | 18 | 50% | $28.9M | N/A |
What Is Frequency Therapeutics?
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
keywords:N/A
$180.3M
Total Funding
100
Number of Employees
$24M
Revenue (est)
-9%
Employee Growth %
$177.9M
Valuation
N/A
Accelerator
Frequency Therapeutics News
Frequency Therapeutics, a Woburn, Mass.-based clinical-stage biotechnology company creating a new class of drugs based on small molecule stimulation of dormant stem cells within the body which we refer to as Progenitor Cell Activation (PCA), closed a $42m Series B financing. The round, which br ...
Premium US-based Frequency Therapeutics, a clinical-stage biotechnology company creating small molecule drugs, has completed raising $42 million in its Series B funding round led by Taiwania Capital Management and Axil Capital. Continue reading this story with a subscription to DealStreetAsia. ...
Frequency Therapeutics, a Woburn, Mass.-based clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, closed a $62.0m Series C financing. The round was led by Perceptive Advisors and a syn ...
Woburn, Mass.-based Frequency Therapeutics did not disclose the number of shares it seeks to sell or the price range of the offered units.
Hearing loss affects millions of Americans but to date, there are no FDA-approved medicines to treat them. Frequency Therapeutics is ...
Frequency Therapeutics has appointed Dana Hilt to serve as its chief medical officer, the same position he held at Lysosomal Therapeutics.
Other Companies in Woburn
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $22.2M | 101 | 3% | N/A |
#2 | $15.2M | 105 | N/A | N/A |
#3 | $25.6M | 107 | 9% | N/A |
#4 | $15.3M | 109 | 7% | N/A |
#5 | $31.6M | 109 | 3% | N/A |
Frequency Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-04-12 | $32.0M | A | CoBro Ventures | Article |
| 2019-01-08 | $42.0M | B | Taiwania Capital Management | Article |
